Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05791695 · ClinicalTrials.gov registry record
A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022
A clinical trial, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- 155,413
- Enrollment target
NCT05791695: Completed study, sponsored by Regeneron Pharmaceuticals.
NCT05791695 is a clinical trial that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 155,413 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05791695 has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- 155,413 participants
- Enrollment target
Study Summary
Specific study objectives include: * To describe patient and provider characteristics for aflibercept patients and aflibercept user injections by aflibercept dispensing device, overall, and stratified by time (quarterly, annually). * To estimate the annual and quarterly incidence of intraocular inflammation (IOI) and suspected endophthalmitis for aflibercept user injections by aflibercept dispensing device. Secondary objectives • To estimate the annual incidence of IOI and suspected endophthalmitis for aflibercept user injections by dispensing device, stratified by indication for use, history of IOI, and provider characteristics.
Interventions
- OTHER Non Applicable
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155,413 participants |
| Start Date | 2022-09-16 |
| Est. Completion | 2023-09-15 |
What the finished NCT05791695 record still lists
NCT05791695 is an observational study that tracks outcomes without assigning an intervention. Its 155,413 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Non Applicable is the first listed.
NCT05791695 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05791695 about?
NCT05791695 is a clinical study titled "A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022". Specific study objectives include: * To describe patient and provider characteristics for aflibercept patients and aflibercept user injections by aflibercept dispensing device, overall, and stratified by time (quarterly, annually). * To estimate the annual and quarterly incidence of intraocular inf...
What is the current status of trial NCT05791695?
This trial is currently completed. The enrollment target is 155,413 participants. The study started on 2022-09-16. Estimated completion is 2023-09-15.
What interventions are being tested in trial NCT05791695?
The interventions under investigation include: Non Applicable (OTHER).
Who is sponsoring clinical trial NCT05791695?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI